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An Extracellular Matrix-Liposome Composite, a Novel
Extracellular Matrix Delivery System for Accelerated Tissue
Regeneration
Keel Yong Lee, Huong Thanh Nguyen, Agustina Setiawati, So-Jung Nam, Minyoung Kim,
Il-Gyu Ko, Won Hee Jung, Kevin K. Parker,* Chang-Ju Kim,* and Kwanwoo Shin*
The unfolded states of fibronectin (FN) subsequently induce the formation of
an extracellular matrix (ECM) fibrillar network, which is necessary to generate
new substitutive tissues. Here, the authors demonstrate that negatively
charged small unilamellar vesicles (SUVs) qualify as candidates for FN
delivery due to their remarkable effects on the autonomous binding and
unfolding of FN, which leads to increased tissue regeneration. In vitro
experiments revealed that the FN-SUV complex remarkably increased the
attachment, differentiation, and migration of fibroblasts. The potential
utilization of this complex in vivo to treat inflammatory colon diseases is also
described based on results obtained for ameliorated conditions in rats with
ulcerative colitis (UC) that had been treated with the FN-SUV complex. Their
findings provide a new ECM-delivery platform for ECM-based therapeutic
applications and suggest that properly designed SUVs may be an
unprecedented FN-delivery system that is highly effective in treating UC and
inflammatory bowel diseases.
1. Introduction
Fibronectin (FN) plays an essential role in the wound healing
process due to its ability to form an extracellular matrix (ECM)
and to regulate cellular activities.[1] In addition to the ability to
bind together and form FN fibrils, FN molecules have various
recognition and binding sites in their structure, and these sites
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favor interactions with various cell types,
growth factors, cytokines, and other ECM
proteins, such as collagen, and heparin.[2–4]
Soluble FN is a folded dimeric protein
whose subunits are composed of three
types of repeating modules, I, II, and III
with alternatively spliced V domains, which
account for various isoforms of plasma
FN.[5,6] Among the three modules, FN type
III (FNIII) is the largest and most com-
mon repeat.[2,4] Once in contact with the
cell surface, FNIII domains will be recog-
nized by integrin proteins on the cell mem-
brane and subsequently undergo an unfold-
ing process caused by cell-traction forces,
which induces FN fibrillogenesis.[3,7,8] Un-
folding is, therefore, essential in FN func-
tionalization, which is the target of FN-
based material fabrication.[1,9] Although the
cell binding sites within the FNIII mod-
ule are exposed on the surface, the active
domains, which are known to be phosphorylation sites, are usu-
ally hydrophobic. These domains are buried within FNIII mod-
ules in the folded state due to hydrophobic interactions and are
maintained by intramolecular ionic bonds.[10,11] Therefore, un-
folding FN is crucial not only for enhancing the elasticity of fi-
bronectin fibrils but also for exposing the buried sites that are
known to display enzymatic activities and to regulate many cel-
lular activities.[12]
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The use of soluble, compact FN has been successful in improv-
ing wound-healing treatments after being unfolded by various
mechanisms.[13,14] Some examples of wounds considered thus
far are diabetes- and radiation-induced cutaneous wounds in rats
or mice.[15,16] Corneal epithelial wounds have also been reported
to heal more quickly after having been treated using eye drops
containing a soluble FN and hyaluronan combination.[17] Vari-
ous efforts have also been made to develop large-scale fibronectin
networks which might be adopted to facilitate the wound heal-
ing process[18–20] Nevertheless, recent reports have revealed that
supplying cells with unfolded FN, compared to compact FN, im-
proves the wound-healing efficiency more remarkably. For exam-
ple, Le et al. reported an enhanced formation of FN fibrils after
denaturation of FN by using urea, leading to improved platelet
adhesion.[21] In 2018, Christophe et al. adopted rotary jet spin-
ning to produce unfolded FN fibers and confirmed that its use
effectively enhanced wound healing.[22] Most recently, Neale et al.
demonstrated that the aligned network of unfolded FN was crit-
ical for directing fibroblast orientation and migration.[23] These
studies suggest that for higher wound-healing efficiency, FN used
in tissue regeneration should undergo certain procedures to in-
duce changes in its conformation. Some methods for doing so
include physical binding on different substrates, modifying sur-
faces with chemical groups, or using gold nanoparticles.[24–28] Al-
though unfolded FN has been shown to perform better than com-
pact FN, previously reported methods for unfolding FN have had
limited clinical application due to the complexity of the processes
required. Urea-induced FN unfolding has also been used, but it
has not been widely used in in vivo experiments due to its poten-
tial cytotoxicity .[29–31]
In this study, to tackle the above issues, we demonstrate a po-
tential FN-unfolding platform that uses negatively charged, small
unilamellar vesicles (SUVs) for FN delivery. These SUVs are sim-
ply produced by using a unique composition of lipids so that the
surface of the SUV not only enhances direct binding but also in-
duces the unfolding of FN. The effects of FN delivered by our
SUV system were investigated using a variety of cell-based assays
to evaluate all aspects of cellular activities, including growth, dif-
ferentiation, and migration. An in vivo wound-healing model of
ulcerative colitis (UC) was adopted to evaluate the sufficiency of
the unfolded FN that was delivered. Collectively, this FN-SUV sys-
tem provides a platform that can be easily integrated into existing
drug delivery systems due to its high biocompatibility, homoge-
neous production via spontaneous FN binding, and, provision-
ally, ease of formulation with a variety of drugs.
2. Results
2.1. FN Stretched after Binding on Negatively Charged
Liposomes
For critical cellular functions to be accessed, compact FN must
be unfolded to expose buried domains.[32] Hence, our first ef-
fort was to determine the composition of lipids that not only en-
hanced the binding efficiency of FN but also induced conforma-
tional changes of FN prior to its delivery to cells. The optimized
lipid composition of SUVs was found to be zwitterionic:net neg-
ative:cholesterol at a ratio of 3:2:1. An appropriate ratio of 1,2-
dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) resulted in a net
negative charge on the surface of the SUV (Figure 1a). An analo-
gous giant unilamellar vesicle (GUV) system was developed with
the same lipid composition but a hundredfold increase in size
(20–30 μm on average) (Figure 1b,c). The analogous GUVs al-
lowed us to observe the binding directly by using confocal imag-
ing. FN tended to form insoluble aggregates when it was incu-
bated with neutral vesicles (Figure 1b and Figure S1a, Supporting
Information), but was attached evenly on the surfaces of nega-
tively charged GUVs (Figure 1c and Figure S1b, Supporting Infor-
mation). The strongly favorable and selective binding of FN to a
negatively charged lipid is obvious in phase-separated GUVs with
two lipid phases (Figure S2, Supporting Information). The liq-
uid order (Lo) phase contained zwitterionic sphingomyelin, and
the liquid disorder (Ld) phase contained DOPS and other unsatu-
rated lipids, constructing the negative portion of the membrane.
Under the same experimental conditions, FN was observed only
in the Ld phase (green fluorescence) and not in the Lo phase of
the same GUV (Figure S2b, Supporting Information). This result
clearly confirmed that a negatively charged vesicle system selec-
tively enhanced FN binding.
Direct evaluation of the binding of FN on SUVs with an appro-
priate size for cell delivery was much more sophisticated because
SUVs (average radius of 200 nm) are remarkably smaller than
GUVs (average radius of 20 μm). Images obtained from cryogenic
transmission electron microscopy (cryo-TEM) showed that the
SUVs incubated with FN had a membrane that was significantly
thicker (thickness d = 8.3 ± 0.6 nm) than the membrane contain-
ing only lipids (d = 4.4 ± 0.6 nm) (Figure 1d,e). The thickness
of the membrane comprises the lipid membrane itself, which is
≈4–5 nm, and an additional FN layer, if any, on the membrane.
This result implied that FN was, indeed, bound to the SUVs,
which was observed as an increase in the membrane thickness.
In addition to performing single-SUV thickness measurements,
we measured the size distribution of the entire SUV population
by using the dynamic light scattering (DLS) method (Figure S3,
Supporting Information). The results showed that the average
size of the SUV population increased from 140.3 to 178.3 nm and
that the curve shifted to the right (larger size), indicating that the
size of the SUV had been increased during incubation in an FN
solution.
In addition to enhancing the binding of FN on the surface,
negatively charged SUVs induced conformational changes. The
stretching of FN was measured by using fluorescence resonance
energy transfer (FRET) with FN labeled with donor–acceptor dyes
(FN-DA). Four molar (4 m) guanidinium chloride (GdnHCl), one
of the strongest denaturants, was used as a positive control [33]
(Figure S4, Supporting Information). Figure 1f shows that the
IA/ID ratio of FN-DA incubated with SUVs was comparable to
that of FN-DA incubated in 4-m GdnHCl (0.38 ± 0.06 and 0.34 ±
0.13, respectively) and was significantly lower than that of FN-DA
incubated in phosphate buffered saline (PBS), which was used
for SUV hydration, or sucrose, which was used for GUV hydra-
tion (1.18 ± 0.2 and 1.19 ± 0.05, respectively). FRET was also ac-
complished on GUVs coated with FN-DA; the IA/ID ratio of FN-
DA was decreased after incubation with GUVs (from 0.92 ± 0.11
to 0.18 ± 0.06 after incubation) (Figure 1g,h). This result verified
that stretching of FN had also occurred on the surfaces of GUVs.
Taken together, the negatively charged SUV system is a suitable
vehicle for delivering FN in an active, unfolded conformation.
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Figure 1. Fibronectin binds to negatively charged vesicles, which changes its conformation. a) Illustration showing how a negatively charged surface
induces binding and stretching of fibronectin (FN). b,c) Confocal images of a GUV (red) without (b) and with (c) DOPS-containing GUVs after incubation
with FN (green) for 24 h (n = 5 independent experiments per group). d) Cryo-TEM images of an SUV and magnified views of its membrane (right panels)
after incubation with (lower) and without FN (upper). e) Summary of the membrane thicknesses observed in (d) (n = 10 per group). f) Data from FRET
showing the intensity ratio IA/ID observed in double-labeled FN diluted in PBS, 4 m GdnHCl, or sucrose, or incubated with SUVs (n = 3 per group). IA
and ID are the acceptor and the donor fluorescence intensities, respectively. g) Single-vesicle FRET using confocal imaging showing the donor and the
acceptor intensities in GUVs after 6 and 24 h of incubation with FN. h) Summary of single-vesicle FRET from (g) showing the intensity ratios IA/ID after
6 and 24 h of incubation with FN and GUVs (n = 5 per group). Data represent the means ± standard deviations (SDs)
2.2. FN-SUV Increased Cell Attachment and Proliferation at a
Greater Rate than Soluble FN
FN has been utilized in cell and tissue cultures to strengthen
cell attachment, proliferation, and migration.[25,27,34–36] We hy-
pothesized that the conformational changes induced by bind-
ing to negatively charged SUVs would enhance the above cellu-
lar functions of FN to a greater extent than its compact form.
We performed in vitro experiments using human neonatal der-
mal fibroblast (HDFn) cells, as they play essential roles in tis-
sue repair. The fate of FN after having been delivered to HDFn
cells was probed with either green (FN-SUV) or red (FN) fluores-
cent indicators. Figure 2a illustrates the formation of a FN ma-
trix after having approached the surface of the HDFn cells. In
both groups, FN fibrils were found to colocalize with their mem-
brane receptor, integrin 𝛼5 (Figure 2b). However, more FN fib-
rils were produced when FN was delivered by using SUVs (Fig-
ure S5, Supporting Information). Our results suggest that FN-
SUVs burst and expanded when they came into contact with the
surface of the HDFn cells by the interaction between integrin
𝛼5 and FN fibrils (Figure 2c). This event was not observed on
samples with aggregated FN without SUVs (data not shown),
indicating that stretched FN promoted interaction with the cell
surface. As we observed that SUVs unfolded FN in advance of
the interaction with the cell membrane, we predicted that this
would subsequently increase the adhesion of cells to the cul-
ture substrate when they are treated with FN-SUV. Figure 2d
shows that trypsinized HDFn cells (green, labelled with GFP)
had limited attachment to the culture dish. However, when FN-
SUV was added, the number of attached and active fibroblasts
(seen as spindle-shaped cells with long lamellipodia) on the disk
bottom was significantly increased.[37] A quantitative compari-
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Figure 2. Delivery of FN-SUVs enhances fibrillogenesis and cell attachment. a) Schematics of FN-SUV on the HDFn surface. b) Immunostaining images
illustrating binding patterns of FN fibrils (red or green) on HDFn surfaces (n = 3 independent experiments per group). White represents the integrin
𝛼5-FITC antibody. c) Images of 7.5-min time intervals showing the untangling process of FN-SUV bundles on the surfaces of HDFn cells (n = 3). d)
Live-cell images showing changes in the morphologies of HDFn cells after 20 h of incubation with PBS (Ctrl), FN, or FN-SUVs (n = 3 independent
experiments per group). e) Attachment rate of HDFn cells quantified by the area of the cells attached to the dish’s surface (n = 3 per group). f) Live cell
images showing the areas of the FN matrix formed on the surfaces of HDFn cells after incubation with FN or FN-SUVs (n = 5 independent experiments
per group).
son of cell attachment among the experimental groups was per-
formed by calculating the total area of attached cells, as shown
in Figure 2e. Moreover, the area of the FN matrix was signif-
icantly greater when FN was delivered by SUVs, implying en-
hanced extracellular matrix formation (Figure 2f and Video S4,
Supporting Information). Although FN promoted cell attach-
ment, stretched FN made the surfaces of GUVs unfavorable for
bacteria, particularly Staphylococcus aureus (S. aureus), an organ-
ism that often causes opportunistic infections on skin and leads
to tissue damage, as described in a previous study.[38] S. au-
reus was incubated with different types of GUVs (Figure S6 and
Videos S1–S3, Supporting Information). A large number of bac-
teria (white) were found on collagen-coated GUVs (COL-GUVs).
In contrast to the case with the bare lipid GUVs, the bacteria
were hardly present on the FN-coated GUVs, suggesting that us-
ing the stretched FN as a wound healing agent had advantages
in preventing unwanted bacterial infection during the healing
process.
2.3. SUV-Induced Stretched FN Promoted Cell Migration
When tissue is injured, released cytokines attract fibroblasts from
the surrounding area.[1] During this time, fibroblasts are acti-
vated and migrate towards the injured area with the recruit-
ment of ECM proteins including FN.[39,40] We tested whether the
stretching of FN would promote the migration rate of fibrob-
lasts, as it has been shown to enhance ECM formation. Figure 3a
shows representative images cut from Videos S5–S7, Supporting
Information, illustrating the movements of HDFn-GFP cells as
a function of time. Single cells were tracked, and the average mi-
gration speeds (micrometer per minute) were compared among
groups. As we expected, the migration speed increased when
SUVs (green circles) were used for FN delivery (Figure 3a,b). This
enhancement may result from the formation of a denser FN ma-
trix, which facilitates cell adhesion and migration. The expansion
of the FN matrix over time can be seen clearly in Figure S7 and
Video S11, Supporting Information.
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Figure 3. FN-SUV treatment accelerates the migration rate of HDFn cells. a) Representative images tracking the migration speed of single HDFn cells in
the control (Ctrl), FN- and FN-SUV-treated groups. b) Summary of the single-cell migration speeds in the control, FN- and FN-SUV-treated HDFn cells
(n = 25, from 5 independent experiments). c) in vitro scratch assays were performed in the control, FN- and FN-SUV-treated HDFn cells to compare
the rates of migration. Representative images were extracted from the time series at 0 and 12.5 h. d) Results of quantitative analyses of the recovery
areas covered by migrated cells as described in (c). Data were collected from the same optical field at 1 h time intervals over 15 h (n = 4 independent
experiments).
In vitro scratch assays were used to assess the cell migration
speed to evaluate cell migration.[41] To ensure the reproducibil-
ity of the experiments, we set up an incubation chamber in the
confocal microscope system and continuously observed a specific
injured area for at least 16 h. Representative images at 0 and 12.5
h for each group are shown in Figure 3c; the corresponding time-
lapse images are shown in Videos S8–S10, Supporting Informa-
tion. The results revealed that among the experimental groups,
the gap closed at the highest rate in the FN-SUV-treated group,
with 60.3 ± 4.3% of the gap area being covered by HDFn cells
after 15 h compared to only 33.5 ± 4.2% in the FN-treated group
(Figure 3d) with higher directionality and more elongated mor-
phology (Figure S8, Supporting Information). Insignificant pro-
liferation among all groups was observed during the first 24 h,
which showed that the cell migration assays were unbiased, with
minimal contribution from cell proliferation (Figure S9, Support-
ing Information).
2.4. FN-SUV Improved Wound Healing in Rats with Ulcer Colitis
More Significantly than Compact FN
The healing effects of FN in vivo were described previously by
using a wide range of wound models in different species, such
as rabbits, mice, and guinea pigs.[16,42,43] Existing evidence from
previous studies indicates that in inflammatory bowel-related dis-
eases, such as ulcerative colitis (UC) and Crohn’s disease, the
level of FN in the plasma is decreased significantly.[9,44] In this
present study, the healing performance of FN-SUVs was further
assessed in vivo using an UC model for rats. An approved proto-
col using 4% acetic acid was applied to induce UC in the colon,
followed by a 10-day treatment strategy with either FN or FN-
SUVs (Figure S10, Supporting Information). After treatment, the
entire colons of the rats were removed to compare changes in
morphology, wet weights, and various tissue damage markers
(Figure 4a). As shown in Figure 4b, the FN-SUV-treated group
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Figure 4. FN-SUV treatment improves the healing process of acid-induced ulcers in rat colons. a) Hypothesized schematic of FN-SUV treatment in the
rat colon. b) Gross morphologies of the intestines removed from the rats after 10 days of treatment. In the control group, the healthy colon wall can
be seen to be thin and smooth with no mucus while in the colitis-induced groups, the wall of the colon is swollen and filled with blood and mucus.
Various degrees of colitis can be seen among the different treatments. c,d) Ulcer score and stool score of the control and the colitis-induced groups as
described in (a) (n = 10 per group). e) Colon wet weight of the control and the colitis-induced groups as described in (a) (n = 10 per group). p values
were calculated using Student’s t-tests. f,g) Expression levels of the inflammatory indicators COX-2 (n = 5 per group) (d) and iNOS (n = 6 per group)
(e). d–g) Error bars indicate the SDs.
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showed remarkably thinner and smoother colon walls with less
mucus (less tissue damage) than the FN-treated group. Moreover,
mesalamine- and FN-SUV-treated groups had decreased the ul-
cer scores and stool score as a result of the improvements of his-
tological alterations, including ulceration, mucosal atrophy, sub-
mucosal edema, and inflammatory cells infiltration (Figure 4c,d
and Figure S11, Supporting Information). In addition, FN-SUV-
treated colons had significantly lower wet weights than those
treated with FN alone, indicating that SUV-FN treatment reduced
inflammation and swelling in the colons (Figure 4e).
Colon tissues after either FN or FN-SUV treatment were fur-
ther analyzed semi-quantitatively for inflammatory markers, in-
cluding tumor necrosis factor (TNF)-𝛼, interleukin (IL)-1𝛽, IL-
6, cyclooxygenase (COX)-2, and inducible nitric oxide synthase
(iNOS). However, the differences in the levels of tumor necrosis
factor (TNF)-𝛼, IL-1𝛽, and IL-6 expressions between the FN and
the FN-SUV groups were insignificant (Figure S12, Supporting
Information) whereas COX-2 and iNOS expressions were down-
regulated in rats treated with FN-SUV, suggesting that the un-
folding of FN via the SUV may expose domains that commu-
nicate with cells via these two pathways (Figure 4f,g).[45,46] The
inhibitions of the COX-2 and the iNOS expressions in our in
vivo model clearly showed that inflammation was effectively de-
creased in the experimental UC model when the FN-SUV treat-
ment was administered.[47]
3. Discussion
Many attempts have been made to unfold FN prior to its reach-
ing the cell. However, an appropriate approach to unfolding FN
for tissue regeneration applications is still a challenge. The un-
folding of FN requires the breakage of intramolecular bonds and
hydrophobic interactions, which can be induced by using either
chemicals[21,33] or mechanical forces.[10,22] The pH or salt concen-
tration can induce the stretching of FN, but this reversible change
is hard to maintain for cell delivery. Moreover, the solution must
be similar to the physiological environment. The improper re-
moval of a denaturant will otherwise potentially result in negative
effects on live cells and tissues.[33]
The adsorption and unfolding facilitated by chemical mod-
ifications raise a risk of cytotoxicity.[24–27] On the other hand,
approaches using mechanical forces to unfold FN usually ex-
ploit solid substrates and polymers with low biocompatibility.
The most promising approach might be to produce nanofibers
from soluble FN by using mechanical forces.[22,48] However, the
FN nanofiber production remains challenging, as the use of
the fabrication technique may not always be possible in labo-
ratories. Nonetheless, FN nanofibers are more appropriate for
dressing materials and cutaneous wound treatment than for the
treatment of bowel diseases. Despite major efforts to deliver
ECM or FN to damaged tissues via surface-modified substrates,
the fabrication of these materials remains very complex, and
these substrates usually have to be removed from the body after
having been applied, which is not appropriate for deep, closed
wounds.[49,50] In contrast, negatively charged SUVs are highly
biocompatible, which have been used for drugs and mRNA-base
vaccines.[51–53] All the lipids (e.g., DOPC, DOPS, and DOPE)
used in this research have been clinically approved and are being
commercialized.[54] Accordingly, we managed to develop a nega-
tively charged SUV system that had negligible toxicity and could
safely deliver the desired therapeutic materials.[51,55] In addition,
the preparation of self-assembled SUVs in an aqueous solution,
followed by the autonomous binding and unfolding of FN, was
much simpler and afforded higher yields than any other method.
The adsorption and unfolding of FN on liposomes were re-
ported by Halter et al. in 2005.[56] Both gel-phase and liquid-phase
liposomes were considered for FN selective binding, but only li-
posomes composed of lipids that had high melting temperature
(Tm) or existed in the gel phase at room temperature, such as
DPPC (Tm = 41 °C) or DSPC (Tm = 55 °C), were observed to bind
and unfold FN effectively.[56] Apart from gel-phase liposomes, we
have sufficient experimental evidence to prove that FN is able to
bind and unfold on liquid-phase liposomes composed of lipids
with Tm < 0 °C under the condition that a negatively charged
lipid (DOPS) is added. Due to the low Tm values of the lipids
used, the fabrication of negatively charged SUVs is simplified and
can be performed at room temperature. Nevertheless, the in vitro
and vivo effects of FN-SUV have not been characterized, although
the adsorption and unfolding of FN on liposomes was reported
in detailed in Halter’s study. Therefore, the negatively charged
SUV system has significant advantages over previous FN-based
wound healing materials in terms of fabrication, cytotoxicity, and
biocompatibility.
4. Conclusions
Collectively, we confirmed that negatively charged SUVs could
effectively unfold FN bound to their surfaces. Subsequently, the
SUVs enhanced the effects of FN on HDFn migration and pro-
liferation. In vivo experiments showed that rats with UC that
had been treated with FN-SUVs improved faster than rats treated
with only soluble FN. The abundant amount of FN in the plasma
is an advantage of using FN as a potential tissue regeneration
material.[1,9,44] FN also possesses an exceptional property for
wound healing, as stretched FN disrupts the binding of S. aureus,
a common cause of infections in humans.[38]
We conclude that negatively charged SUVs are ideal vehicles
for functional FN delivery. The system has the capability to carry
and unfold FN with high biocompatibility and safety and can be
used as a platform for incorporating drugs that accelerate wound
healing. Further studies are expected to discover the mechanisms
underlying the efficacy of the SUV-FN delivery system.
5. Experimental Section
Preparation of Small Unilamellar Vesicles (SUVs) with Negatively Charged
Surfaces: Multilamellar liposomes were first prepared by blending
DOPC:DOPE:DOPS:cholesterol in a ratio of 2:1:2:1 to make a mixture with
a total concentration of 5 mg of lipids per milliliter in chloroform. One
milliliter of the lipid blend in a black glass vial was blown dry using N2
gas for 2 h to completely remove the solvent. The dried lipids were then
rehydrated with 1 × PBS (pH 7.4) by using a vortex mixer at room temper-
ature for 60 min. The lamellarity of the liposomes was reduced by using 5
cycles of freezing in liquid nitrogen and thawing in a water bath at 40 °C to
break down the outer bilayers. Finally, the vesicles were extruded by using a
mini-extruder set (Avanti, Inc.) to pass them through a 200-nm membrane
filter 11 times. The day before experiment, a fibronectin (FN) solution that
had been previously diluted in deionized water was added to make an FN
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or FN-SUV solution with a final concentration of 10 μg mL−1, followed by
incubation at 37 °C overnight.
Preparation of Giant Unilamellar Vesicles (GUVs): A lipid mixture with
a composition of either DOPC:DOPE:DOPS:cholesterol (2:1:1:1 molar ra-
tio) for negatively charged GUVs or DOPC:DOPE:cholesterol (2:1:1) for
neutrally charged GUVs was prepared with a concentration of 1 mg mL−1.
Approximately 30 μL of the lipid mixture was deposited on ITO glass (30-
Ohm sheet resistance) and quickly dried by using flowing N2 gas. The
lipids were continuously dehydrated in a vacuum desiccator for ≈1 h. A
silicon ring with a thickness of 1 mm was inserted between two ITO glass
slides to make space for the hydrate solution. For observations under a
light microscope, the lipids were rehydrated with an inner solution con-
taining 200-mm sucrose and 2-mm MES (pH 4.2) and were later diluted
with an outer solution containing 200-mm glucose and 2-mm MES (pH
4.2). Before confocal microscopy, a fibronectin (FN) solution that had been
previously diluted in deionized water was added to make an FN-GUV so-
lution with a final concentration of 10 μg mL−1, followed by incubation at
37 °C overnight. GUVs were imaged by using confocal microscopies (Le-
ica SP8 and ZEISS LSM 710) at the Bioimaging Center of the Advanced
Bio-Interface Core Research Facility, Sogang University.
Preparation of Fibronectin (FN): Fibronectin was in powder form be-
fore being diluted into deionized water to make a FN stock solution at
concentration of 1 mg mL−1. FN solution was stored at −20 °C or long-
term storage and thawed slowly at 4 °C before use.
FN Conjugation for Fluorescence Resonance Energy Transfer (FRET) Anal-
ysis: Fibronectin (FN) was subsequently labeled with Alexa-546 C5
maleimide on its cysteine residues and with Alexa-488 NHS succinimidyl
ester on its lysine residues. Lyophilized FN diluted with PBS to a concen-
tration of 1 mg mL−1 was denatured in the chaotropic agent guanidine
hydrochloride (GdnHCl, 8 m) at a ratio of 1:1 (v/v) and then incubated
with Alexa 546 maleimide at a molar ratio of 1:30. Excess fluorescence dye
was removed through dialysis by using a slide-A-lyzer dialysis cassette with
a 10000 Dalton MW cut-off in 0.1-m sodium bicarbonate (NaHCO3) at pH
8.5. The buffer was changed twice every 2 h before being stored overnight
at 4 °C. The initial conformation of labeled FN was confirmed using spec-
trofluorometry. Afterwards, the labeled FN was incubated for one hour with
Alexa 488 NHS succinimidyl ester at a ratio of 1:70 (mol/mol). Doubly la-
beled FN with a donor and an acceptor dye (FN-DA) was separated from
the free dyes by using a PD-10 column (pre-equilibrated with PBS). The
ratio of the donor intensity to the acceptor intensity per FN dimer (IA/ID)
was determined by measuring the fluorescences of FN-DA at 280, 496,
and 556 nm. For long-term storage, FN-DA was stored in 10% glycerol at
−80 °C.
Characterization of FN-SUV Incorporation by Using Cryogenic Transmis-
sion Electron Microscopy (Cryo-TEM): FN was incubated overnight with
preformed SUVs at a ratio of 1:5 (w/w). Immediately after incubation, sam-
ples of either SUVs or FN-SUVs were preserved by vitrification and sup-
ported by Quantifoil (R 2/2, 400-mesh holey-carbon grid, Quantifoil Micro
Tools). Vitrified samples were prepared by applying a 3-μL drop of sample
suspension to a cleaned grid, blotting away the excess with filter paper,
and immediately plunging the grid into liquid ethane. Grids were stored
under liquid nitrogen until being transferred to the transmission electron
microscope for imaging. Electron microscopy was performed using a Talos
L120C electron microscope (FEI, Hillsboro, OR, USA) operating at 120 kV.
Vitreous ice grids were transferred into the electron microscope by using
a cryostage that maintained the grids at a temperature below −170 °C. An
image of each grid was acquired on multiple scales to assess the overall
distribution of the specimen. Images were collected using a 4k × 4k Ceta
CMOS camera at a search magnification of 5000 and a final magnification
of 29 000 to 280 000 at an underfocus of ≈2.5 μm. After the identification of
potentially suitable target areas for imaging at lower magnifications, pairs
of highly magnified images were acquired using the UI V1.6 Talos soft-
ware. ImageJ software was used to analyze the intralamellar distances in
the original, high-resolution images collected using the microscope (4096
× 4096 pixels).
Fluorescence Resonance Energy Transfer (FRET) Analysis: The donor
fluorophores Alexa NHS-488 labelled lysine residues and acceptor flu-
orophores (Alexa maleimide-546) labelled cysteines on FN modules on
FN. There are five lysine and two cysteine residues in each FN monomer.
For every FN-FRET batch, we calculated the ratio of donors to acceptors
per FN dimer by measuring the absorbances of FN-DA at 280, 496, and
556 nm and using published extinction coefficients for dyes.[57–59] For
each dimer molecule used in this study, we calculated an average label-
ing ratio of 8.5 ± 0.5 donors and 3.3 ± 0.84 acceptors per FN dimer. Two
acceptor-cysteines are presented in FNIII7 and FNIII15 on each monomer
(for molecules for dimer). In native FN (folded), FNIII module locates in
cryptic domain stabilizing through ionic interaction between arms; while,
in extended FN, FNIII module loss of secondary structure leading dis-
tance increase of donor and acceptor (>12 nm) and decrease the energy
transfer.
The fluorescence intensity of FN-DA was measured using a standard
fluorescence spectrophotometer (Hitachi F-7000) with excitation of the
donor at 488 nm. The positive controls were measured using a series
of GdnHCl concentrations from 0 to 4 m. The data from FRET measure-
ments over a range of denaturant concentrations was used to plot the
correlation of the FRET efficiency with the degree of FN unfolding.[60]
FN-DA was incubated overnight with preformed SUVs at a ratio of 1:5
(w/w) with gentle rocking to enhance the binding. Then, cryo-TEM and
FRET were exploited to characterize the incorporation and the unfolding
of FN on the SUVs. The background fluorescence was measured using
SUVs in solution, and the negative control was measured using FN-DA
in PBS at the same concentration as in the FN-SUV sample, but without
SUVs.
Colocalization, Attachment Area, and Fibril Formation Imaging: HDFn
cells were cultured in DMEM (FBS 10%, 1% Pen-Strep). For integrin ob-
servation, FITC-conjugated integrin 𝛼5 antibody was used. FN was diluted
in PBS and used at a concentration of 10 μg mL−1. For cell attachment ex-
periments, HDFn-GFP cells were detached using trypsin-EDTA when the
confluence had reached 80% and were then transferred to a new culture
dish, treated with non-labeled FN and imaged every hour in an on-stage
incubator. For quantification of the area of the FN fibrils, HDFn-GFP cells
were treated with lissamine-rhodamine-labeled FN and imaged. In-situ im-
ages as a function of time were taken using an on-stage incubator with CO2
and temperature control. Images and videos were processed using ImageJ
and Zen software.
In Vitro Scratch Assay: In migration experiments, GFP-HDFn cells were
cultured in T75 flasks to reach a confluence of 80–90% and were then
transferred to 35-mm dishes for continuous culturing over 24 h with 10%
FBS for attachment. When cells had formed a confluent monolayer, the
medium was replaced with low-serum DMEM (0.4% FBS) every 24 h
to minimize the effects of proliferation on the migration speed and to
avoid unexpected apoptosis.[41] The distance that a single cell moved was
tracked using ImageJ.
A scratch mimicking a wound was created using a p200 pipette tip by
scraping a straight line across the center of the dish. Cell debris was then
washed away gently with 2 mL of low-serum medium before being sup-
plemented with either PBS, FN, or FN-SUV. The final concentration of
FN or FN-SUV solution is 10 μg mL−1 in all experiments, unless other-
wise stated. The 35-mm dish was placed in a stage-top incubator (Zeiss,
USA) with a CO2 supply and a controlled temperature of 37 °C to obtain
the same optical field during the image acquisition. Images of GFP-HDFn
cells migrating to the scratch were recorded using confocal microscopy
(ZEISS LSM 710, USA) in a time series mode at 1 h intervals for at least
15 h.
Ulcerative Colitis Rat Model: We followed the Guidelines for the Care
and Use of Animals approved by the National Institute of Health Coun-
cil for the management and use of animals for laboratory tests. The ex-
perimental design was approved by the Institutional Care and Use Com-
mittee of Kyung Hee University (KHUASP(SE)-15-085). Rats were divided
into the following five groups (n = 10 in each group): healthy group (nega-
tive control), ulcerative colitis (UC)-induced group (positive control), UC-
induced/mesalamine-treated group, UC-induced/FN-SUV-treated group,
and UC-induced/FN-treated group.
Induction of Ulcerative Colitis by Using Acetic Acid: Ulcerative colitis
(UC) was induced by using acetic acid, as previously described.[61] The rats
were anesthetized with Zoletil 50 (10 mg kg−1; Vibac Laboratories, Carros,
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France). Animals were fasted for 48 h for UC preparation. A stainless-steel
feeding needle (round tip, 16 gauge) was then carefully inserted into the
colon of a rat with the tip being 8 cm proximal to the anus. Then, 4% acetic
acid (Sigma Chemical Co., St. Louis, MO, USA) in 0.9% saline (1.0 mL)
was injected into the lumen of the colon. The control group underwent
intracolonic injection with saline instead. The rats were maintained in a
supine Trendelenburg position for 5 min to prevent leakage of the injected
acetic acid solution.
UC Treatment: The UC treatments were administered three days af-
ter acetic acid injection. The dosages for the groups were as follows:
mesalamine (4 g/100 mL, Asacol Enema, Tillotts Pharma, AG, Swiss), FN-
SUVs (20 μg mL−1 FN, 100 μg mL−1 SUVs), and FN (20 μg mL−1). For
drug administration, the rats were confined in an acrylic cylinder (diame-
ter: 6 cm, length: 20 cm, height: 10 cm) without anesthesia. A stainless-
steel feeding needle (round tip, 16 gauge) with a syringe was then carefully
inserted through the anus into the damaged site. Then, each drug (1.0 ml)
was injected into the lumen of the colon once a day for 10 days after in-
duction of UC.
H&E Staining and Evaluated of Ulcer Score: Histological changes in
colon tissues were detected by H&E staining as previously described by
Jeon et al.[62] The slides were immersed in Mayer’s hematoxylin (DAKO,
Glostrup, Denmark) for 30 s and then rinsed with tap water until clean. The
slides were then immersed in eosin (Sigma Chemical Co., St. Louis, MO,
USA) for 10 s and rinsed again with water. The slides were dried at room
temperature and then immersed in 95% ethanol twice, in 100% ethanol
twice, in 50% ethanol and 50% xylene twice, and in 100% xylene twice. The
slides were covered with coverslips of Permount (Fisher Scientific, New
Jersey, NJ, USA). The parameters evaluated for ulcer score were: histolog-
ical ulceration, mucosal atrophy, submucosal edema, and inflammatory
cells infiltration. Each parameter was scored on a scale from zero (nor-
mal) to 3 (severe damage) according to the criteria described by Mehra-
bani et al. .[63] Total ulcer score was calculated by summing up individual
scores for each rat.[63,64]
Western Blotting: Colon tissues were homogenized on ice, lysed with
lysis buffer, and then centrifuged at 14 000 rpm for 30 min. The amount
of protein in each sample was quantified using a Bio-Rad colorimetric
protein assay kit (Bio-Rad, Hercules, CA, USA). Sodium dodecyl sulfate-
polyacrylamide gels were used to separate proteins (30 μg), after which
the separated proteins were transferred onto nitrocellulose membranes.
Goat COX-2 antibody (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), mouse iNOS antibody, and mouse 𝛽-actin antibody (1:1000; Santa
Cruz Biotechnology) were used as the primary antibodies. Horseradish
peroxidase-conjugated anti-mouse antibodies (1:2000; Vector Laborato-
ries, Burlingame, CA, USA) for iNOS, 𝛽-actin, and COX-2 were used as
secondary antibodies. Membrane transfer was conducted at 4 °C by us-
ing a cold pack and pre-chilled buffer. An enhanced chemiluminescence
(ECL) detection kit (Santa Cruz Biotechnology) was used for band detec-
tion. Molecular Analyst (version 1.4.1, Bio-Rad) was used to analyze the
detected bands.
Data Analysis: All of the images, except for the in vivo experiments,
were analyzed using either ImageJ (1.51) or Zen software (2.3 SP1, Black
edition). Migration of each cell was analyzed by using the plug-in Mtrack2
in ImageJ. The recovery areas were quantified using ImageJ. For cell area
study, the intensity of GFP-expressing HDFn per area was calculated from
the confocal images by using ImageJ. The orientation in degrees of grey-
scale GFP-expressing HDFn images were analyzed through the Orienta-
tionJ plug-in ImageJ software.
Using the Image-Pro plus computer-assisted image analysis system
(Media Cybernetics Inc., Silver Spring, MD, USA), the area of UC in each
sample was measured with help of a light microscope (Olympus, Tokyo,
Japan). For relative quantification, the results in the control group of west-
ern blot were set as 1.00.
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